LoqoaTape exerts analgesic and anti-inflammatory effects by inhibiting cyclooxygenase (COX) activity and reducing prostaglandin synthesis.

1、 Drug name

1. Product Name: LoqoaTape

2. Common name: Esflurbiprofen/MenthaOil

2、 Indications

Used for pain relief and anti-inflammatory treatment of osteoarthritis (osteoarthritis).

3、 Specifications and characteristics

1. Specification: Each sticker measures 10 cm x 14 cm (with a weight of 1.73 grams/140 square centimeters), containing 40 milligrams of ibuprofen and 36.2 milligrams of peppermint oil from the Japanese Pharmacopoeia.

2. Appearance: A colorless to pale yellow transparent paste with a special aroma. The paste extends onto the support, and the paste surface is covered with an isolation film.

4、 Main components

Active ingredients: Esflurbiprofen, Mentha Oil

5、 Usage and dosage

1. Usage: Apply once a day to the affected area.

2. Usage limit: Do not use more than 2 patches at a time.

3. Caution: As the systemic exposure during the use of 2 patches is equivalent to the regular dose of oral flurbiprofen, the daily dose should not exceed 2 patches. It should be avoided to use other anti-inflammatory and analgesic agents that are expected to have systemic effects as much as possible. If they must be used together, they should be limited to the minimum necessary dosage and the patient's condition should be closely monitored.

6、 Dose adjustment

1. Leakage treatment: This product is a once daily patch. If you forget to apply it, you can apply it immediately on the same day and replace it at the regular time the next day. If it is close to the next application time, skip this time and apply the next application at the regular time. Do not use double the dosage at once.

2. Vomiting treatment: This product is a transdermal absorption preparation and is not suitable for the vomiting treatment principles of oral medications.

7、 Medication precautions

1. Application area: Only for the affected skin and should not be used on wounds, eczema, rashes, or other abnormal areas.

2. Skin reaction: If there are skin symptoms (dermatitis, erythema, itching, rash, etc.) at the application site, measures such as stopping medication or discontinuing use should be taken according to the symptoms.

3. Long term use: During long-term use, regular urine tests, blood tests, and liver function tests should be performed.

4. Special condition: For elderly people or patients with wasting diseases accompanied by high fever, close attention should be paid to whether there is excessive temperature drop, collapse, limb cooling, etc. after medication.

8、 Medication for special populations

1. Pregnant women:

Late pregnancy women: prohibited. Animal experiments have shown that it may lead to maternal death, delayed delivery, decreased birth rates, and increased stillbirths. There are reports that the use of other non steroidal anti-inflammatory and analgesic topical preparations in late pregnancy women can cause fetal ductus arteriosus constriction.

Pregnant women (excluding late pregnancy): Use only when treatment benefits outweigh risks. It should be limited to the minimum necessary dosage, and the amniotic fluid volume and fetal ductus arteriosus contraction should be appropriately confirmed based on gestational age and administration days.

2. Breastfeeding women should consider the benefits of treatment and breastfeeding when deciding whether to continue or discontinue breastfeeding. Animal experiments have shown that drugs can be secreted through breast milk and can inhibit birth weight gain at high exposure levels.

3. Children: Clinical trials for children have not yet been conducted, and safety is unknown.

4. Elderly people: Side effects are more likely to occur, and the patient's condition should be closely monitored, limited to the minimum necessary dosage.

5. Liver/kidney dysfunction:

Patients with severe liver/kidney dysfunction: contraindicated.

Patients with a history of liver/kidney dysfunction or low renal blood flow: may worsen or induce disorders, use with caution.

9、 Adverse reactions

1. Major side effects (frequency unknown):

Shock and allergic reactions.

Acute kidney injury, nephrotic syndrome.

Gastrointestinal bleeding.

Aplastic anemia.

Asthma attack induced (aspirin induced asthma).

Toxic epidermal necrolysis, mucocutaneous ocular syndrome, and exfoliative dermatitis.

Consciousness disorders, loss of consciousness accompanied by spasms.

Myocardial infarction and cerebrovascular disorders.

2. Other side effects:

Applicable areas: dermatitis (above 5%), erythema/itching/eczema/rash (below 1-5%), internal bleeding/irritation/pigmentation (below 1%), swelling/discoloration/pain/heat sensation (frequency unknown).

Systemic: Dizziness, abdominal discomfort/gastritis/peptic ulcer/abdominal pain/nausea/vomiting/oral inflammation, constipation/diarrhea/loss of appetite/abnormal stool color, elevated AST/ALT and other liver function abnormalities, elevated blood urea/creatinine levels, etc.

10、 Contraindications

1. Patients with peptic ulcers.

2. Patients with severe blood abnormalities.

3. Patients with severe liver function impairment.

4. Patients with severe renal dysfunction.

5. Patients with severe cardiac dysfunction.

6. Patients with severe hypertension.

7. Individuals with a history of allergies to the ingredients of this medication or to flurbiprofen.

8. Aspirin induced asthma or those with a history of it.

9. Patients currently taking enoxacin, lomefloxacin, norfloxacin, and prulifloxacin.

10. Women in late pregnancy.

11、 Drug interactions

1. And use taboos:

Enrofloxacin, Lomofloxacin, Norfloxacin, Prulifloxacin: May cause spasms.

2. And please note:

Other new quinolone antibiotics (such as ofloxacin): may cause spasms, it is best to avoid using them in combination.

Coumarin anticoagulants (warfarin): may enhance anticoagulant effects and require dosage adjustment.

Lithium preparations (lithium carbonate): may cause an increase in blood lithium concentration, and blood lithium concentration needs to be monitored.

Methotrexate: may increase its blood concentration.

Thiazides/loop diuretics (hydrochlorothiazide, furosemide): may weaken the diuretic effect.

Corticosteroids such as methylprednisolone may mutually enhance gastrointestinal side effects.

CYP2C9 inhibitors (such as fluconazole): may increase the blood concentration of ibuprofen.

12、 Storage method

1. Store at room temperature.

2. The validity period is 24 months.

3. After opening the aluminum inner bag, attention should be paid to moisture-proof and light shielded storage.

13、 Manufacturer

Manufacturer and seller: Taisho Pharmaceutical Co., Ltd

Loqoa Tapeinformation